Brief: Quanterix Announces New Agreement To Advance Blood Based Alzheimer's Disease Detection
24/10/2023 01:32
Oct 23 (Reuters) - Quanterix Corp QTRX.O :
* QUANTERIX ANNOUNCES NEW AGREEMENT TO ADVANCE BLOOD BASED
ALZHEIMER'S DISEASE DETECTION
* QUANTERIX - AGREEMENT PROVIDES QUANTERIX LICENSE TO
EXTENSIVELY
STUDIED P-TAU 217 ANTIBODIES
* ANNOUNCED SIGNING OF A LICENSE AGREEMENT WITH JANSSEN
SCIENCES
IRELAND UC (JANSSEN), A JOHNSON & JOHNSON (J&J) COMPANY
Source text for Eikon: ID:nBw8QnLYha
Further company coverage: QTRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Quanterix
See all newsBrief: Alzpath And Quanterix Expand Strategic Licensing Agreement To Advance Next Generation Alzheimer's Disease Biomarker Research
Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Quanterix Corporation expected to post a loss of 46 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 46 cents a share - Earnings Preview